Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. - Wikidata - awgldk - TriplyDB

Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer.

Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer.

http://www.wikidata.org/entity/Q46516617

about

Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers The fate of chemoresistance in triple negative breast cancer (TNBC)Beyond taxanes: the next generation of microtubule-targeting agents The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents.Microtubules and their role in cellular stress in cancer Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis.Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma.Ixabepilone development across the breast cancer continuum: a paradigm shift.Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane.Role of the progesterone receptor for paclitaxel resistance in primary breast cancer.Drug resistance and the role of combination chemotherapy in improving patient outcomes.Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancer The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.Management of advanced breast cancer with the epothilone B analog, ixabepilone Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.Tubulin: an example of targeted chemotherapy.Taxane benefit in breast cancer--a role for grade and chromosomal stability.Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models.An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence?Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors.Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.Collapsin response mediator protein 2 is involved in regulating breast cancer progression.The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis.The relationship between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase, excision repair cross-complementation group 1 and class III β-tubulin, and the therapeutic effect of S-1 or carbopla Prognostic value of vascular endothelial growth factor receptor 1 and class III β-tubulin in survival for non-metastatic rectal cancer

P2860

Q21296833-7046C3F4-24FD-4305-BD3B-003109B44E0F Q26775232-435C2699-FA45-4612-8711-FFABFB5B9012 Q26865369-484CBD7E-F9DC-485F-AF69-4CEB4FA97C6E Q27010233-4580AD4D-48B4-4FE4-BC60-93CF7B2D5C75 Q27851983-866EA6C4-A771-4CAB-BC45-5DC710113307 Q28244659-0CCEAE49-3C28-4EF0-9FE9-C06799383956 Q28534786-CD33416B-BA28-479E-B845-1A4B66DE2C49 Q33630855-23218A08-2AF8-41A8-8436-D3A92FF089FE Q33770927-5EE87484-2EE3-49D8-A2CE-57115DB46804 Q33903541-1B62F03A-6E27-4E49-BA36-2A2064E5B36A Q34206647-27F84E8F-D8C8-430A-A659-A1495E97E95E Q34274930-05925C1E-1A3D-4D15-9412-8DF194042568 Q34298027-F7CD347D-DAAF-4843-829B-177D7DB3E861 Q34417996-9692C772-56B0-4408-AC85-9399A570A654 Q34428153-94DABB5E-3647-4820-8A0D-1A39C294A754 Q34770077-4E40045A-B67E-40D5-A532-F9025A4CF4C2 Q36244183-7D2CB3F9-2A51-430F-B47C-920342E626AE Q36609702-CCF07EBD-A8D4-43F3-A32F-B0C362557EFD Q36999509-CE3703AA-CBF0-43C2-970C-1B08B11991CC Q37038455-3ED9069B-B9D1-45E3-80B0-95E7844A5E0D Q37083038-55EDE301-58A2-49BC-A98F-40717DA53D7C Q37194315-88B1D420-D59A-4757-8A20-D457F03B1F5C Q37378233-E7187062-BAED-4B58-A71D-3B1F6509E2D0 Q37403186-CCC0A718-32DC-40EF-B68F-E5D89FB65E4F Q37570220-1E984FC1-F8A9-4712-8C5F-1AE01B3CFD81 Q37699264-2936EAA8-EB56-4102-8687-0604B674C9D6 Q38086872-B9B2DCBD-DA56-4E6F-BF24-B0D2024CDBD4 Q38104568-1BF8E408-1335-445A-8F7A-E3B3C9B98BD2 Q38305006-37671ED1-E710-4AD7-8E46-440BA4964DB9 Q38475122-89D9E94A-3400-4D5D-9249-7F72B20E9D53 Q39414846-789D1028-71DE-44FF-A251-EACB4DC5693B Q40074831-CBABC684-AD0C-4468-984A-3D5E96098111 Q41143898-F938FB6F-3E91-45E1-8E9D-CDE69123C22B Q41588399-7F9E3AF0-C2F9-4E89-BF09-4303DC190135 Q43592584-56C11CCE-4C8F-4E2F-A120-B863D8449539 Q50678236-95B5342E-F8DA-4351-8EC9-88D5F264A96A Q55439654-9488C619-E0BF-4B98-B94D-DDB65C23C2D0 Q58566654-EB3AFD63-9E9D-4921-8A15-F5EF1C455510

P2860

Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer.

http://www.wikidata.org/entity/Q46516617

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Biomarkers predictive for clin ...... apy in advanced breast cancer.

@en

Biomarkers predictive for clin ...... apy in advanced breast cancer.

@nl

type

label

Biomarkers predictive for clin ...... apy in advanced breast cancer.

@en

Biomarkers predictive for clin ...... apy in advanced breast cancer.

@nl

prefLabel

Biomarkers predictive for clin ...... apy in advanced breast cancer.

@en

Biomarkers predictive for clin ...... apy in advanced breast cancer.

@nl

P1433

Q46516617-EE3C2BF6-5F66-4CBE-8A42-0F3D3265F7E4

P1476

Q46516617-44DDA86B-1826-4734-921C-F810355F5330

P2093

Q46516617-055C8E11-79CB-428C-AD6D-D93B3B937CD0

Q46516617-464C28FE-6467-4BB9-88BA-06CE56DE4A48

Q46516617-B3F11D14-BB90-43B1-964D-7016215BE437

Q46516617-C84EC691-0F92-4F5B-9750-D16E637DE8C7

Q46516617-EE3AD8F7-01AD-493E-92EE-FBE5797DA284

Q46516617-F211A5D2-853A-4C73-9425-D104DC5D5AD3

Q46516617-FFECE99D-A532-4A21-98B3-EA60928DED45

P304

Q46516617-DB32746B-E8EE-4DB7-AE22-2793690A7D9A

P31

Q46516617-EF4D74B6-DC40-4CE2-BF66-FB4143EDCD30

P356

Q46516617-668A5AF3-389B-4643-BABB-87E12FC4CCDB

P478

Q46516617-4C944B84-FA44-41AA-8FD1-0460F4C87DA2

P50

Q46516617-0F6E60F5-8D3F-4B97-9842-A65602390604

P577

Q46516617-E13B984B-AC2C-469C-A336-96B42AF78AD1

P5875

Q46516617-7000CF60-2FB2-4041-B3D2-131DE007B6DA

P698

Q46516617-99BCD709-77A4-4F1E-86BD-187E94FCD336

P921

Q46516617-2DBDBBCE-B058-4818-A912-56A2C0D5FEC1

P356

P1433

Annals of Oncology

P1476

Biomarkers predictive for clin ...... apy in advanced breast cancer.

@en

P2093

A Chiriatti

http://www.w3.org/2001/XMLSchema#string

A Latorre

http://www.w3.org/2001/XMLSchema#string

A Mangia

http://www.w3.org/2001/XMLSchema#string

A Paradiso

http://www.w3.org/2001/XMLSchema#string

A Zito

http://www.w3.org/2001/XMLSchema#string

F Schittulli

http://www.w3.org/2001/XMLSchema#string

V Lorusso

http://www.w3.org/2001/XMLSchema#string

P304

iv14-19

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDI902

http://www.w3.org/2001/XMLSchema#string

P478

16 Suppl 4

http://www.w3.org/2001/XMLSchema#string

P50

Stefania Tommasi

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7819309

http://www.w3.org/2001/XMLSchema#string

P698

15923415

http://www.w3.org/2001/XMLSchema#string

P921